Association between osteoporosis or osteopenia and taking antiplatelet agents in general US population of NHANES
BackgroundOsteoporosis (OP) and osteopenia are common bone disorders in old age, and lots of patients suffering from OP or osteopenia need to take antiplatelet agents to treat basic diseases. However, clinical data on the link between osteopenia or OP and antiplatelet agents are limited.MethodsData...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2022.945159/full |
| _version_ | 1828152336176906240 |
|---|---|
| author | Hao Lv Hao Lv Jiuxiang Wang Yujun Zhu Zhimu Hu Ziwen Wang Mingzhu Qiao Ting Jiang |
| author_facet | Hao Lv Hao Lv Jiuxiang Wang Yujun Zhu Zhimu Hu Ziwen Wang Mingzhu Qiao Ting Jiang |
| author_sort | Hao Lv |
| collection | DOAJ |
| description | BackgroundOsteoporosis (OP) and osteopenia are common bone disorders in old age, and lots of patients suffering from OP or osteopenia need to take antiplatelet agents to treat basic diseases. However, clinical data on the link between osteopenia or OP and antiplatelet agents are limited.MethodsData in this study were collected and screened from the NHANES from 2013 to 2014 and 2017 to 2018. The variables were extracted from interviews and compared between OP or osteopenia participants and normal. The relationship between OP or osteopenia and taking antiplatelet drugs was analyzed by weighted multivariate logistic regressionResultsAfter excluding individuals who were not eligible and had invalid data, we finally identified 894 participants for inclusion in the study. We found a negative association between OP or osteopenia and taking antiplatelet agents (OR = 0.53; 95% CI, 0.33–0.84; p < 0.05). These results did not change on multiple imputations (OR = 0.32, 95% CI, 0.19–0.56; p <0.01). In the subgroup analyses, the associations were more significant in women (OR = 0.18, 95% CI, 0.05–0.62; p <0.05).ConclusionThis study demonstrated that the association between OP or osteopenia and taking antiplatelet agents was significant. Therefore, it is necessary to confirm the result by extending further research. |
| first_indexed | 2024-04-11T22:09:08Z |
| format | Article |
| id | doaj.art-b792c869ab4e4a0b827fffe925e43577 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-04-11T22:09:08Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-b792c869ab4e4a0b827fffe925e435772022-12-22T04:00:36ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922022-08-011310.3389/fendo.2022.945159945159Association between osteoporosis or osteopenia and taking antiplatelet agents in general US population of NHANESHao Lv0Hao Lv1Jiuxiang Wang2Yujun Zhu3Zhimu Hu4Ziwen Wang5Mingzhu Qiao6Ting Jiang7First Affiliated Hospital, Anhui University of Chinese Medicine, Hefei, ChinaAnhui University of Chinese Medicine, Hefei, ChinaFirst Affiliated Hospital, Anhui University of Chinese Medicine, Hefei, ChinaAnhui University of Chinese Medicine, Hefei, ChinaAnhui University of Chinese Medicine, Hefei, ChinaAnhui University of Chinese Medicine, Hefei, ChinaAnhui University of Chinese Medicine, Hefei, ChinaFirst Affiliated Hospital, Anhui University of Chinese Medicine, Hefei, ChinaBackgroundOsteoporosis (OP) and osteopenia are common bone disorders in old age, and lots of patients suffering from OP or osteopenia need to take antiplatelet agents to treat basic diseases. However, clinical data on the link between osteopenia or OP and antiplatelet agents are limited.MethodsData in this study were collected and screened from the NHANES from 2013 to 2014 and 2017 to 2018. The variables were extracted from interviews and compared between OP or osteopenia participants and normal. The relationship between OP or osteopenia and taking antiplatelet drugs was analyzed by weighted multivariate logistic regressionResultsAfter excluding individuals who were not eligible and had invalid data, we finally identified 894 participants for inclusion in the study. We found a negative association between OP or osteopenia and taking antiplatelet agents (OR = 0.53; 95% CI, 0.33–0.84; p < 0.05). These results did not change on multiple imputations (OR = 0.32, 95% CI, 0.19–0.56; p <0.01). In the subgroup analyses, the associations were more significant in women (OR = 0.18, 95% CI, 0.05–0.62; p <0.05).ConclusionThis study demonstrated that the association between OP or osteopenia and taking antiplatelet agents was significant. Therefore, it is necessary to confirm the result by extending further research.https://www.frontiersin.org/articles/10.3389/fendo.2022.945159/fullosteoporosisosteopeniaantiplatelet agentsNHANEScross-sectional survey |
| spellingShingle | Hao Lv Hao Lv Jiuxiang Wang Yujun Zhu Zhimu Hu Ziwen Wang Mingzhu Qiao Ting Jiang Association between osteoporosis or osteopenia and taking antiplatelet agents in general US population of NHANES Frontiers in Endocrinology osteoporosis osteopenia antiplatelet agents NHANES cross-sectional survey |
| title | Association between osteoporosis or osteopenia and taking antiplatelet agents in general US population of NHANES |
| title_full | Association between osteoporosis or osteopenia and taking antiplatelet agents in general US population of NHANES |
| title_fullStr | Association between osteoporosis or osteopenia and taking antiplatelet agents in general US population of NHANES |
| title_full_unstemmed | Association between osteoporosis or osteopenia and taking antiplatelet agents in general US population of NHANES |
| title_short | Association between osteoporosis or osteopenia and taking antiplatelet agents in general US population of NHANES |
| title_sort | association between osteoporosis or osteopenia and taking antiplatelet agents in general us population of nhanes |
| topic | osteoporosis osteopenia antiplatelet agents NHANES cross-sectional survey |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2022.945159/full |
| work_keys_str_mv | AT haolv associationbetweenosteoporosisorosteopeniaandtakingantiplateletagentsingeneraluspopulationofnhanes AT haolv associationbetweenosteoporosisorosteopeniaandtakingantiplateletagentsingeneraluspopulationofnhanes AT jiuxiangwang associationbetweenosteoporosisorosteopeniaandtakingantiplateletagentsingeneraluspopulationofnhanes AT yujunzhu associationbetweenosteoporosisorosteopeniaandtakingantiplateletagentsingeneraluspopulationofnhanes AT zhimuhu associationbetweenosteoporosisorosteopeniaandtakingantiplateletagentsingeneraluspopulationofnhanes AT ziwenwang associationbetweenosteoporosisorosteopeniaandtakingantiplateletagentsingeneraluspopulationofnhanes AT mingzhuqiao associationbetweenosteoporosisorosteopeniaandtakingantiplateletagentsingeneraluspopulationofnhanes AT tingjiang associationbetweenosteoporosisorosteopeniaandtakingantiplateletagentsingeneraluspopulationofnhanes |